Cardiorenal disease management in type 2 diabetes: An expert consensus

医学 肾脏疾病 肾病科 2型糖尿病 糖尿病 内科学 重症监护医学 疾病 内分泌学
作者
Viswanathan Mohan,Awadhesh Kumar Singh,Abdul Hamid Zargar,Alan Fernandes Almeida,Anil Kumar Bhalla,Jagadish Chander Mohan,Jamshed J Dalal,Manisha Sahay,Padhinhare P. Mohanan,Sanjay Maitra,Sujoy Kumar Ghosh,Tarun Kumar Jeloka,Upendra Kaul,Vinay Sakhuja,Mrinal Kanti Das
出处
期刊:Diabetes and Metabolic Syndrome: Clinical Research and Reviews [Elsevier BV]
卷期号:16 (12): 102661-102661 被引量:2
标识
DOI:10.1016/j.dsx.2022.102661
摘要

The interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D) is well established. We aim at providing an evidence-based expert opinion regarding the prevention and treatment of both heart failure (HF) and renal complications in people with T2D.ology: The consensus recommendations were developed by subject experts in endocrinology, cardiology, and nephrology. The criteria for consensus were set to statements with ≥80% of agreement among clinicians specialized in endocrinology, cardiology, and nephrology. Key expert opinions were formulated based on scientific evidence and clinical judgment.Assessing the risk factors of CVD or CKD in people with diabetes and taking measures to prevent HF or kidney disease are essential. Known CVD or CKD among people with diabetes confers a very high risk for recurrent CVD. Metformin plus lifestyle modification should be the first-line therapy (unless contraindicated) for the management of T2D. Glucagon-like peptide 1 (GLP-1) agonists can be preferred in people with atherosclerotic cardiovascular disease (ASCVD) or with high-risk indicators, along with sodium-glucose cotransporter-2 inhibitors (SGLT2i), whereas SGLT2i are the first choice in HF and CKD. The GLP-1 agonists can be used in people with CKD if SGLT2i are not tolerated.Current evidence suggests SGLT2i as preferred agents among people with T2D and HF, and for those with T2D and ASCVD. SGLT2i and GLP-1RA also lower CV outcomes in those with diabetes and ASCVD, and the treatment choice should depend on the patient profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
July0717_发布了新的文献求助10
刚刚
Hello的应助被Panda采纳,获得10
1秒前
1秒前
耶耶业发布了新的文献求助10
1秒前
YM发布了新的文献求助10
2秒前
小五发布了新的文献求助10
2秒前
Yuyu001完成签到 ,获得积分10
2秒前
K123发布了新的文献求助10
2秒前
April发布了新的文献求助10
3秒前
3秒前
隐形冰之完成签到,获得积分10
3秒前
xxxxxxxxxx发布了新的文献求助10
4秒前
liangchenglyu发布了新的文献求助10
5秒前
csy完成签到,获得积分10
5秒前
7秒前
如意连碧完成签到,获得积分10
7秒前
wangdl_2000完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
可爱的函函的应助被function采纳,获得10
7秒前
净心完成签到,获得积分10
7秒前
8秒前
8秒前
ioi完成签到 ,获得积分10
8秒前
8秒前
supperhappy完成签到,获得积分10
9秒前
chms发布了新的文献求助10
10秒前
10秒前
无极微光的应助被ayeben采纳,获得20
10秒前
CodeCraft的应助被胡萝卜卜采纳,获得10
10秒前
葡萄关注了科研通微信公众号
10秒前
舒心的雨双完成签到,获得积分10
11秒前
BOBO发布了新的文献求助10
11秒前
11秒前
明理飞风完成签到,获得积分10
11秒前
12秒前
大成子发布了新的文献求助10
12秒前
刘一完成签到 ,获得积分10
13秒前
科研究极进化完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128